secwatch / observer

Conexeu Sciences Inc. — fact timeline

Source-grounded facts extracted from Conexeu Sciences Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.

CNXU Conexeu Sciences Inc. JSON
Equity Issuances

Conexeu Sciences Inc. issued 100,000 shares of common stock of common stock to the individual who is a U.S. person for at a price of $0.001 per share.

“On June 8, 2026, the Company issued 100,000 shares of common stock (the " Performance Warrant Shares ") at a price of $0.001 per share upon the exercise of a like number of issued and outstanding performance common stock purchase warrants (the " Performance Warrants "), for gross proceeds of $100.”
Equity Issuances

Conexeu Sciences Inc. issued 416,667 Incentive Warrants of warrant to one warrant holder.

“On June 4, 2026, 416,667 Incentive Warrants were issued to the one Warrant holder.”
Equity Issuances

Conexeu Sciences Inc. issued 416,667 shares of common stock of common stock to one warrant holder for gross proceeds of approximately $166,667.

“On June 4, 2026, Conexeu Sciences Inc. (the " Registrant " or the " Company ") issued 416,667 shares of common stock (the "Warrant Shares"), upon the exercise of a like number of issued and outstanding common stock purchase warrants (the " Warrants "), for gross proceeds of approximately $166,667.”
Governance Changes

Conexeu Sciences Inc.: Increased quorum requirement for stockholder meetings from one-twentieth to one-third of outstanding shares (effective 2026-05-11).

“On May 11, 2026, the Board of Directors of the Company approved an amendment to the bylaws (the " Bylaws ") of the Company in order to increase the quorum requirement for meetings of stockholders from one-twentieth (1/20) of the outstanding shares of the Company entitled to vote at any such meeting, represented in person or by proxy, to one-third (331⁄3%) of the outstanding shares of the Company entitled to vote, represented in person or by proxy.”

Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.